Triple E for HCV ECHO: Program Overview
As the treatment for hepatitis C virus (HCV) continues to advance at an extremely rapid pace with new discoveries and developments over recent years and a rising number of HCV infections among the people who inject drugs (PWID) population, a significant educational need presses practicing health care professionals who manage the care of patients who are at-risk for HCV, including PWID. With safe and highly effective treatments now available for HCV, these health care professionals require a detailed understanding of the importance of screening, accurate diagnosis and proper treatment.
In response, the joint-providership of the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and Chronic Liver Disease Foundation (CLDF) is excited to announce the Triple E for HCV educational initiative, Treatment Expansion in Appalachia. This program expands in to the Appalachian region to create a self-sustaining model for the eradication of HCV via a comprehensive education, screening and treatment pathway.
A key component to this substance abuse center and primary care meeting series will feature tele-mentoring via The ECHO Model™ which dramatically increases access to specialty treatment in rural and underserved areas by providing front-line clinicians with the knowledge and support they need to manage patients with complex conditions. It does this by engaging clinicians in a continuous learning system and partnering them with specialist mentors at an academic medical center or hub.
The ECHO model™ breaks down the walls between specialty and primary care. It links expert specialist teams at an academic ‘hub’ with primary care clinicians in local communities — the ‘spokes’ of the model. Essentially, ECHO® creates ongoing learning communities where primary care clinicians receive support and develop the skills they need to treat a particular condition. As a result, they can provide comprehensive, best-practice care to patients with complex health conditions, right where they live.
Supported by an educational grant from
AbbVie and Gilead Sciences, Inc..